论文部分内容阅读
目的 掌握我国大规模用药前耐药突变在我国HIV 1感染者中流行情况的本底资料。方法 在第二次全国HIV流行病调查 2 0 0 2年样本中随机选取 2 0 % ,对于蛋白酶 (PR)基因区全长和逆转录酶 (RT) 2 0～ 2 30氨基酸位点进行PCR扩增、测序并使用HIVdb DrugResistanceAlgorithm软件进行分析 ,检测耐药相关突变。结果 分别得到 16 4份PR基因区样本和 138份RT基因区样本。PR基因区样本中发现 1份 ( 0 6 1% )样本存在蛋白酶抑制剂 (PI)主要相关突变 ,16 3份 ( 99 39% )样本存在PI次要耐药相关突变。RT基因区样本中发现 8份 ( 5 80 % )具有核苷类逆转录酶抑制剂 (NRTI)耐药相关突变 ,2份 ( 1 4 5 % )存在非核苷类逆转录酶抑制剂 (NNRTI)耐药相关突变。结论 我国未用药HIV感染者中耐药相关突变尚处于低流行状态 ,应当在用药过程中定期监控以减少耐药突变的产生与传播
Objective To grasp the background information about the prevalence of drug-resistant mutations before large-scale drug use in our country. Methods Twenty (20)% of randomly selected samples from the Second National HIV Epidemic Survey in 2002 were PCR amplified from the full length of the protease (PR) gene region and from 20 to 230 amino acid residues of reverse transcriptase (RT) Increased, sequenced and analyzed using the HIVdb DrugResistanceAlgorithm software to detect resistance-associated mutations. Results A total of 16 4 PR gene samples and 138 RT gene samples were obtained. One of the samples (0 6 1%) in the PR gene region showed the major related mutations of protease inhibitors (PI), and the 16 3 (99 39%) of the samples showed PI-related resistance mutations. Eight (58%) of the RT-PCR products were found to be resistant to nucleoside reverse transcriptase inhibitors (NRTIs), and two (14.5%) to nonnucleoside reverse transcriptase inhibitors (NNRTIs) Resistance-related mutations. Conclusion The drug resistance-related mutations in HIV-infected patients in our country are still in a low-prevalence state and should be regularly monitored during drug use to reduce the generation and spread of drug-resistant mutations